Pathognomonic STEW: visible clues to systemic amyloidosis.

Pathognomonic STEW: visible clues to systemic amyloidosis. Proc (Bayl Univ Med Cent). 2017 Jul;30(3):372 Authors: Fred HL, van Dijk HA PMID: 28670093 [PubMed - in process]
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Tags: Proc (Bayl Univ Med Cent) Source Type: research

Related Links:

Publication date: Available online 9 December 2019Source: Journal of American Association for Pediatric Ophthalmology and StrabismusAuthor(s): Mary-Magdalene Ugo Dodd, Natalie Wolkow, Mary Elizabeth Cunnane, Lina Ma, Thaddeus P. Dryja, David Hunter
Source: Journal of American Association for Pediatric Ophthalmology and Strabismus - Category: Opthalmology Source Type: research
Publication date: Available online 10 December 2019Source: Canadian Journal of CardiologyAuthor(s): Margot K. Davis, Nowell M. FineAbstractRecent developments in cardiac amyloidosis have raised awareness of the disease and have advanced diagnostic and treatment strategies. Novel therapies may vastly improve the prognosis of the disease but will be associated with significant costs. Data are needed to inform clinical decisions and to drive resource allocation within the health care system. Many aspects of disease management are unlikely to be addressed by clinical trials and better suited to non-randomized cohort studies, b...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Roy M. John, David L. SternAbstractArrhythmias are a major cause of morbidity and mortality in the course of cardiac amyloidosis (CA). Less commonly, they may be the initial manifestation that lead to the diagnosis. With improved therapeutic interventions for amyloidosis, it is no longer considered a terminal untreatable condition and there is an increasing recognition of the role of cardiac implantable electronic devices in CA. The frequency and nature of arrhythmias is largely determined by the type of amyloidosis. Bradyarr...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Eli Muchtar, Grace Lin, Martha GroganAbstractLight chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most commonly involved organ and the leading determinant of short and long-term survival. Pathogenic free light chains, fragments of intact immunoglobulins, are the amyloidogenic protein and are secreted by clonal bone marrow plasma cells. The goal of therapy is to cut-off the supply of these pathogenic light chains to allow organ r...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
C2N Diagnostics’s detection test for Alzheimer’s disease is showing off some strong data coming out of the 12th Annual Clinical Trials in Alzheimer’s Disease conference. The St. Louis-based company said results from a study show the Aptus-Aβ test strongly predicts the presence of brain amyloidosis in a diverse population. C2N Diagnostics said its blood-based in vitro diagnostic is being developed to predict amyloid PET scan results. It combines into a ratio, the concentration of amyloid beta (Aβ) isoforms Aβ42 and Aβ40 in ...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
Source: Journal of AAPOS - Category: Opthalmology Authors: Tags: Short Report Source Type: research
.
Source: Amyloid: The Journal of Protein Folding Disorders - Category: Biochemistry Authors: Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractFamilial Mediterranean fever is characterized by self-limited attacks of serositis and arthritis. However, substantial number of patients suffer from chronic complications of this disease, primarily involving musculoskeletal system. Treatment for these complications is challenging due to limited evidence. Interleukin-1 (IL-1) antagonists, tocilizumab and anti-tumor necrosis factor (anti-TNF) agents are off-label treatment options for the management of chronic manifestations of FMF, such as secondary (AA) amyloidosis, chronic arthritis and sacroiliitis. This paper presents a case series of four FMF patients who are ...
Source: Rheumatology International - Category: Rheumatology Source Type: research
CONCLUSION: NT-proBNP may be a sensitive but nonspecific biomarker for assessing CA. However, CMR is the only imaging modality that can assess the pathophysiologic background of cardiac hypertrophy and the severity of CA, irrespective of NT-proBNP level. PMID: 31796976 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
More News: Amyloidosis | Universities & Medical Training